HDL cholesterol: All hope is not lost after the torcetrapib setback -Emerging therapeutic strategies on the horizon

American Journal of Therapeutics

Volumn 21, Issue 3, 2014, Pages 222-232

  Verma, Nitin ^a   Figueredo, Vincent M ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

ApoA 1; cardiovascular diseases; HDL C; Hyperlipidemia; Reverse cholesterol transport

Indexed keywords

2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTERASE; DALCETRAPIB; ESTERASE INHIBITOR; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PIOGLITAZONE; PRAVASTATIN; ROSUVASTATIN; RVX 208; SCAVENGER RECEPTOR BI; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; QUINOLINE DERIVATIVE;

ALBUMINURIA; ALCOHOL CONSUMPTION; AMINO ACID SUBSTITUTION; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARBAMOYLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; COMPLEMENT SYSTEM; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; HEART INFARCTION; HUMAN; LIFESTYLE MODIFICATION; LIPID HOMEOSTASIS; MAINTENANCE THERAPY; MICROANGIOPATHY; MORBIDITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; SMOKING CESSATION; SYSTEMIC CIRCULATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CONTROL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; DYSLIPIDEMIAS; LIFESTYLE; PATHOPHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG DESIGN; DYSLIPIDEMIAS; HUMANS; LIFE STYLE; QUINOLINES;

EID: 84900808450     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318249a1b5     Document Type: Article

References (88)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-Analysis of data from 170,000 participants in 26 randomized trials. Cholesterol Treatment Trialists (CTT) Collaboration. Lancet. 2010;376:1670-1681.
2. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
3. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med. 1951;11:480-493.
4. The Emerging Risk Factors Collaboration. Analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007; 22:839-869.
5. Gordon DJ, Rifkind BM. High-density lipoprotein-The clinical implications of recent studies. N Engl J Med. 1989; 321:1311-1316.
6. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62: 707-714.
7. Genest J Jr. Genetics and prevention: a new look at highdensity lipoprotein cholesterol. Cardiol Rev. 2002;10:61-71.
8. Glomset JA, Janssen ET, Kennedy R, et al. Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res. 1966;7:638-648.
9. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-1310.
10. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85: 1234-1241.
11. Nicholls SJ, Cutri B, Worthley SG, et al. Impact of shortterm administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2005;25:2416-2421.
12. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91: 9607-9611.
13. Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
14. Rong JX, Li J, Reis ED, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104:2447-2452.
15. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation. 2001;103: 3047-3050.
16. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935-1941.
17. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
18. Barter PJ. Hugh Sinclair lecture: the regulation and remodeling of HDL by plasma factors. Atheroscler Suppl. 2002;3:39-47.
19. Barter PJ, Nicholls S, Rye KA, et al. Anti inflammatory properties of HDL. Circ Res. 2004;95:764-772.
20. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111:1543-1550.
21. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti inflammatory properties of HDL. J Clin Invest. 2007;117:746-756.
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-3421.
23. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high density lipoprotein cholesterol, and regression of coronary atherosclerosis. J Am Med Assoc. 2007;297:499-508.
24. AthyrosVG,Mikhailidis DP, PapageorgiouAA, et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004;20: 627-637.
25. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-Term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
26. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101:20B-26B.
27. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110: 3512-3535.
28. Benyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol. 2006;70:1844-1849.
29. Perry CM. Extended-release niacin (nicotinic acid)/laropiprant. Drugs. 2009;69:1665-1679.
30. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
31. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med. 1999;341:410-418.
32. Keech A, Simes RJ, Barter P, et al. Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366:1849-1861.
33. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:850-852.
34. Buse JB, Bigger JT, Byington RP, et al. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007; 99:21i-33i.
35. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-IMilano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc. 2003;290:2292-2300.
36. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Bethesda, MD: NIH; 2007.
37. Calabresi L, Sirtori CR, Paoletti R, et al. Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. Curr Atheroscler Rep. 2006;8:163-167.
38. Bielicki JK, Oda MN. Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wildtype apolipoprotein A-I. Biochemistry. 2002;41:2089-2096.
39. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998; 97:780-785.
40. Calabresi L, Canavesi M, Bernini F, et al. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-I Milano dimer. Biochemistry. 1999;38:16307-16314.
41. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3:144-153.
42. Tardif JC, Gregoire J, LAllier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc. 2007;297:1675-1682.
43. Angelin B, Parini P, Eriksson M. Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl. 2002;3: 23-30.
44. Spieker LE, Sudano I, Hu rlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
45. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944-2948.
46. Brewer HB Jr. Focus on high-density lipoproteins in reducing cardiovascular risk. Am Heart J. 2004;148(Suppl): S14-S18.
47. RodriguezaWV, Klimuk SK, Pritchard PH, et al. Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim Biophys Acta. 1998;1368:306-320.
48. Williams KJ, Werth VP, Wolff JA. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect Biol Med. 1984;27:417-431.
49. Navab M, Hama S, Hough G, et al. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-nullmice. Circulation. 2003;108:1735-1739.
50. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005;25:1325-1331.
51. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med. 2006;3:540-547.
52. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-Amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290-292.
53. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:3215-3220.
54. Bloeden LT, Dunbar RL, Duffy D, et al. Oral administration of the apolipoprotein A-I mimetic peptide D-4F in humans with CHD improves anti-inflammatory function after a single dose. Circulation. 2006;114(Suppl):II-288.
55. Wool GD, Vaisar T, Reardon CA, et al. An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J Lipid Res. 2009;50:1889-1900.
56. McNeill E. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Curr Opin Investig Drugs. 2010;11:357-364.
57. Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and highdensity lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580-2589. Erratum in: J Am Coll Cardiol. 2010;56:825.
58. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.
59. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. J Am Med Assoc. 2008;299:2777-2788.
60. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
61. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27:257-260.
62. Nicholls SJ, Brennan DM, Wolski K, et al. Changes in levels of high-density lipoprotein cholesterol predict the impact of torcetrapib on progression of coronary atherosclerosis: insights from illustrate. Circulation. 2007; 116:II-127.
63. Inazu A, Brown ML, Hesler CB, et al. Increased highdensity lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
64. Haraki T, Inazu A, Yagi K, et al. Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer proteindeficiency. Atherosclerosis 1997;132:229-236.
65. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
66. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomized, double-blind trial. Lancet. 2007;370:153-160.
67. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.
68. Macdonald DL, Terry TL, Agellon LB, et al. Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1583-1588.
69. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapibinduced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465-1473.
70. A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients. Bethesda, MD: NIH; 2008.
71. Cannon CP, Dansky HM, Davidson M, et al. DEFINE investigators. Design of the define trial: determining the efficacy and tolerability of CETP inhibition with anacetrapib. Am Heart J. 2009;158:513-519.e3.
72. Maugeais C, Tietge UJ, Broedl UC, et al. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation. 2003;108:2121-2126.
73. Jin W, Millar JS, Broedl U, et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest. 2003;111:357-362.
74. Badellino KO, Wolfe ML, Reilly MP, et al. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med. 2006;3:e22.
75. Davidson M, Meyer PM, Haffner S, et al. Increased highdensity lipoprotein cholesterol predicts the pioglitazonemediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008;117:2123-2130.
76. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the periscope randomized controlled trial. J Am Med Assoc. 2008; 299:1561-1573.
77. Nissen SE, Nicholls SJ,Wolski K, et al. Effects of a potent and selective PPAR-A agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. J Am Med Assoc. 2007;297: 1362-1373.
78. Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113:90-97.
79. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99:7604-7609.
80. Li AC, Glass CK. PPAR-and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res. 2004;45:2161-2173.
81. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529-541.
82. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176-1184.
83. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. J Am Med Assoc. 2008;299:1265-1276.
84. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199-2211.
85. Vajo Z, Terry JG, Brinton EA. Increased intra-Abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis. 2002;160:495-501.
86. Pelkman CL, Fishell VK, Maddox DH, et al. Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women. Am J Clin Nutr. 2004; 79:204-212.
87. De Oliveira E, Silva ER, Foster D, et al. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation. 2000;102:2347-2352.
88. Garrison RJ, Kannel WB, Feinleib M, et al. Cigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis. 1978;30:17-25.